Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …

In patients with idiopathic pulmonary fibrosis (IPF), the effects of antifibrotic agents on the
prognosis remain unclear. This study aimed to investigate the impact of antifibrotic treatment …

Background Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing
interstitial lung disease of unknown origin. Recently, nintedanib and pirfenidone …

In addition to facilitating healthcare delivery planning, reliable information about prognosis is
essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This …

Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …

Background There are substantial advances in diagnosis and treatment for idiopathic
pulmonary fibrosis (IPF), but without much evidence available on recent mortality and …

Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …

Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its
treatment. Study Selection and Data Extraction: All articles with data from randomized …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …